Author:
Zheng Yuandong,Zhang Hua,Liu Mengling,Li Guangze,Ma Sheng,Zhang Zhe,Lin Hongda,Zhan Yan,Chen Zhendong,Zhong Dafang,Miao Liyan,Diao Xingxing
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Subject
Pharmaceutical Science,Pharmacology
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor;The Journal of Clinical Pharmacology;2024-08-14
2. Mass balance study of [14C]SHR0302, a selective and potent JAK1 inhibitor in humans;Xenobiotica;2023-02-01
3. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023
4. Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats;Cancer Chemotherapy and Pharmacology;2022-10-25
5. Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension;Acta Pharmacologica Sinica;2022-06-08